Breast cancers

Estrogen and progesterone receptor status as a predictor of in vitro chemotherapeutic response

Carl A. Bertelsen, Armando E. Giuliano, David H. Kern, Barry D. Mann, Denise Roe, Donald L. Morton

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Although clinical observations have shown that estrogen receptor-positive (ER+) breast tumors are more responsive to hormonal therapy than ER-negative (ER-) tumors, it remains controversial whether ER status can predict chemotherapeutic response. To determine if there was any correlation between estrogen and progesterone values and in vitro chemosensitivity to various anticancer drugs, clonogenic (CA), estrogen (ERA), and progesterone (PRA) assays on breast cancers were performed on 100 patients. Clonogenic assays were performed using the double-layer soft agar technique with continuous drug exposures. ERAs and PRAs were performed using the charcoal-coated dextran method. Chemosensitivity was defined as 50% inhibition of colony formation. ERA was considered positive if ≥5 fmole/mg cytosol and PRA positive if ≥10 fmole/mg cytosol. Significant tumor growth (> 30 colonies/plate) was achieved in 81 100 assays. ERA and PRA values were not predictive of colony formation in vitro. Of all agents or combinations of agents tested (L-PAM, 5-FU, MTX, adriamycin, vinblastine, cis-plat, FAC, CMF), only the response to 5-FU correlated significantly with ERA. Eight of 11 (73%) of the ER- tumors were sensitive to 5-FU, whereas only 6 20 (30%) of ER+ tumors were sensitive (P < 0.05). ER- tumors were also more likely to be sensitive to CMF (P = 0.09) and adriamycin (P = 0.07) than ER+ tumors. PRA values were not predictive of chemosensitivity, nor did combining PRA and ERA enhance the predictive value of ERA alone.

Original languageEnglish (US)
Pages (from-to)257-263
Number of pages7
JournalJournal of Surgical Research
Volume37
Issue number4
DOIs
StatePublished - 1984
Externally publishedYes

Fingerprint

Progesterone Receptors
Estrogen Receptors
Breast Neoplasms
Fluorouracil
Neoplasms
Cytosol
Doxorubicin
Progesterone
Estrogens
Melphalan
Vinblastine
Charcoal
Dextrans
Pharmaceutical Preparations
Agar
In Vitro Techniques
Growth

ASJC Scopus subject areas

  • Surgery

Cite this

Breast cancers : Estrogen and progesterone receptor status as a predictor of in vitro chemotherapeutic response. / Bertelsen, Carl A.; Giuliano, Armando E.; Kern, David H.; Mann, Barry D.; Roe, Denise; Morton, Donald L.

In: Journal of Surgical Research, Vol. 37, No. 4, 1984, p. 257-263.

Research output: Contribution to journalArticle

Bertelsen, Carl A. ; Giuliano, Armando E. ; Kern, David H. ; Mann, Barry D. ; Roe, Denise ; Morton, Donald L. / Breast cancers : Estrogen and progesterone receptor status as a predictor of in vitro chemotherapeutic response. In: Journal of Surgical Research. 1984 ; Vol. 37, No. 4. pp. 257-263.
@article{27a4266232f84530940ce0f281e806d2,
title = "Breast cancers: Estrogen and progesterone receptor status as a predictor of in vitro chemotherapeutic response",
abstract = "Although clinical observations have shown that estrogen receptor-positive (ER+) breast tumors are more responsive to hormonal therapy than ER-negative (ER-) tumors, it remains controversial whether ER status can predict chemotherapeutic response. To determine if there was any correlation between estrogen and progesterone values and in vitro chemosensitivity to various anticancer drugs, clonogenic (CA), estrogen (ERA), and progesterone (PRA) assays on breast cancers were performed on 100 patients. Clonogenic assays were performed using the double-layer soft agar technique with continuous drug exposures. ERAs and PRAs were performed using the charcoal-coated dextran method. Chemosensitivity was defined as 50{\%} inhibition of colony formation. ERA was considered positive if ≥5 fmole/mg cytosol and PRA positive if ≥10 fmole/mg cytosol. Significant tumor growth (> 30 colonies/plate) was achieved in 81 100 assays. ERA and PRA values were not predictive of colony formation in vitro. Of all agents or combinations of agents tested (L-PAM, 5-FU, MTX, adriamycin, vinblastine, cis-plat, FAC, CMF), only the response to 5-FU correlated significantly with ERA. Eight of 11 (73{\%}) of the ER- tumors were sensitive to 5-FU, whereas only 6 20 (30{\%}) of ER+ tumors were sensitive (P < 0.05). ER- tumors were also more likely to be sensitive to CMF (P = 0.09) and adriamycin (P = 0.07) than ER+ tumors. PRA values were not predictive of chemosensitivity, nor did combining PRA and ERA enhance the predictive value of ERA alone.",
author = "Bertelsen, {Carl A.} and Giuliano, {Armando E.} and Kern, {David H.} and Mann, {Barry D.} and Denise Roe and Morton, {Donald L.}",
year = "1984",
doi = "10.1016/0022-4804(84)90186-0",
language = "English (US)",
volume = "37",
pages = "257--263",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Breast cancers

T2 - Estrogen and progesterone receptor status as a predictor of in vitro chemotherapeutic response

AU - Bertelsen, Carl A.

AU - Giuliano, Armando E.

AU - Kern, David H.

AU - Mann, Barry D.

AU - Roe, Denise

AU - Morton, Donald L.

PY - 1984

Y1 - 1984

N2 - Although clinical observations have shown that estrogen receptor-positive (ER+) breast tumors are more responsive to hormonal therapy than ER-negative (ER-) tumors, it remains controversial whether ER status can predict chemotherapeutic response. To determine if there was any correlation between estrogen and progesterone values and in vitro chemosensitivity to various anticancer drugs, clonogenic (CA), estrogen (ERA), and progesterone (PRA) assays on breast cancers were performed on 100 patients. Clonogenic assays were performed using the double-layer soft agar technique with continuous drug exposures. ERAs and PRAs were performed using the charcoal-coated dextran method. Chemosensitivity was defined as 50% inhibition of colony formation. ERA was considered positive if ≥5 fmole/mg cytosol and PRA positive if ≥10 fmole/mg cytosol. Significant tumor growth (> 30 colonies/plate) was achieved in 81 100 assays. ERA and PRA values were not predictive of colony formation in vitro. Of all agents or combinations of agents tested (L-PAM, 5-FU, MTX, adriamycin, vinblastine, cis-plat, FAC, CMF), only the response to 5-FU correlated significantly with ERA. Eight of 11 (73%) of the ER- tumors were sensitive to 5-FU, whereas only 6 20 (30%) of ER+ tumors were sensitive (P < 0.05). ER- tumors were also more likely to be sensitive to CMF (P = 0.09) and adriamycin (P = 0.07) than ER+ tumors. PRA values were not predictive of chemosensitivity, nor did combining PRA and ERA enhance the predictive value of ERA alone.

AB - Although clinical observations have shown that estrogen receptor-positive (ER+) breast tumors are more responsive to hormonal therapy than ER-negative (ER-) tumors, it remains controversial whether ER status can predict chemotherapeutic response. To determine if there was any correlation between estrogen and progesterone values and in vitro chemosensitivity to various anticancer drugs, clonogenic (CA), estrogen (ERA), and progesterone (PRA) assays on breast cancers were performed on 100 patients. Clonogenic assays were performed using the double-layer soft agar technique with continuous drug exposures. ERAs and PRAs were performed using the charcoal-coated dextran method. Chemosensitivity was defined as 50% inhibition of colony formation. ERA was considered positive if ≥5 fmole/mg cytosol and PRA positive if ≥10 fmole/mg cytosol. Significant tumor growth (> 30 colonies/plate) was achieved in 81 100 assays. ERA and PRA values were not predictive of colony formation in vitro. Of all agents or combinations of agents tested (L-PAM, 5-FU, MTX, adriamycin, vinblastine, cis-plat, FAC, CMF), only the response to 5-FU correlated significantly with ERA. Eight of 11 (73%) of the ER- tumors were sensitive to 5-FU, whereas only 6 20 (30%) of ER+ tumors were sensitive (P < 0.05). ER- tumors were also more likely to be sensitive to CMF (P = 0.09) and adriamycin (P = 0.07) than ER+ tumors. PRA values were not predictive of chemosensitivity, nor did combining PRA and ERA enhance the predictive value of ERA alone.

UR - http://www.scopus.com/inward/record.url?scp=0021689587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021689587&partnerID=8YFLogxK

U2 - 10.1016/0022-4804(84)90186-0

DO - 10.1016/0022-4804(84)90186-0

M3 - Article

VL - 37

SP - 257

EP - 263

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 4

ER -